Back to Dove Press podcast topics » International Journal of Chronic Obstructive Pulmonary Disease » International Journal of COPD podcast series » The impact of triple therapy: Mortality in COPD

The impact of triple therapy: Mortality in COPD

Dr Marc Miravitlles is back to discuss mortality analyses with Dr Richard Russell.¹ They will review what the guidelines recommend for initial and follow-up treatment of COPD, who should receive inhaled corticosteroids and how we should interpret mortality analyses in the COPD field.^2–4 Dr Russell will then dive into a new publication on the use of FEV3/FEV6 in early airways disease identification,⁵ before highlighting what’s hot on social media. This week, the focus is on Lacing Up for Lungs and promoting an active and healthy lifestyle. Don’t miss out!

¹ Miravitlles M, et al. Am J Respir Crit Care Med 2021;203:A2251;
² Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;
³ Chalmers JD, et al. Eur Respir J 2020;55:2000351;
⁴ Suissa S & Ariel A. Eur Respir J 2018;52:1801848;
⁵ Yee N, et al. Chest 2021; doi: 10.1016/j.chest.2021.10.046

Disclosures
Dr Marc Miravitlles has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Grifols, Menarini, Novartis, Rovi, Sandoz and Zambon. He reports consulting fees from AstraZeneca, Atriva Therapeutics, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Inhibrx, Laboratorios Esteve, Mereo Biopharma, Novartis, ONO Pharma, Palobiofarma, pH Pharma, Sanofi, SL Spin Therapeutics, Takeda, and Verona Pharma, and research grants from Grifols.

Bio:

Dr Marc Miravitlles
Dr Marc Miravitlles is a Senior Researcher and Consultant at Vall d’Hebron University Hospital, Barcelona, Spain. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines on COPD, including the American Thoracic Society and ERS guidelines on exacerbations of COPD. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD and the coordinator of the Spanish National Guidelines for COPD

This series of podcasts are intended for healthcare professionals only.

The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.

Download transcript

Publish time: 25 April 2022

Episode number: 12

Duration: 17 minutes 44 seconds

DOI: 10.2147/PODCAST.COPD.12